World's Best Scientists 2026 revealed!
Kurt A. Schalper

Kurt A. Schalper

D-Index & Metrics

Biology and Biochemistry

D-Index
71
Citations
24400
World Ranking
6531
National Ranking
3042

Overview

Kurt A. Schalper is affiliated with Yale University in the United States. Their research predominantly spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research. This broad expertise supports scholarship in cancer immunotherapy and biomarkers as well as immunotherapy and immune responses.

Their main research topics include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Lung Cancer Treatments and Mutations
  • Immune cells in cancer
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Single-cell and spatial transcriptomics

Schalper has contributed to multiple scientific publications, notably in venues such as:

  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Regular and Young Investigator Award Abstracts

Recent significant publications by Schalper include:

  • "Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors" (2020) in Nature Medicine
  • "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer" (2022) in New England Journal of Medicine
  • "CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity" (2020) in Immunity
  • "Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial" (2020) in The Lancet Oncology
  • "Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels" (2022) in JAMA Oncology

The scientist frequently collaborates with peers in the field, including:

  • Roy S. Herbst
  • David L. Rimm
  • Jonathan W. Riess
  • Sarah B. Goldberg
  • Vamsidhar Velcheti

Best Publications

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Programmed death ligand-1 expression in non-small cell lung cancer.

    Vamsidhar Velcheti;Kurt A Schalper;Daniel E Carvajal;Valsamo K Anagnostou

  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Jun Wang;Miguel F. Sanmamed;Ila Datar;Tina Tianjiao Su

  • Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

    Joseph McLaughlin;Gang Han;Kurt A. Schalper;Daniel Carvajal-Hausdorf

  • Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

    Ziming Wang;Ethan G. Aguilar;Jesus I. Luna;Cordelia Dunai

  • Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

    Scott Gettinger;Jungmin Choi;Katherine Hastings;Anna Truini

  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity.

    Álvaro Teijeira;Saray Garasa;María Gato;Carlos Alfaro

  • Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

    Deborah B. Doroshow;Miguel F. Sanmamed;Katherine Hastings;Katerina Politi

  • Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis

    Steve Lu;Julie E. Stein;David L. Rimm;Daphne W. Wang

  • Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

    Kurt A. Schalper;Maria E. Rodriguez-Ruiz;Ricardo Diez-Valle;Alvaro López-Janeiro

  • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.

    Kurt A. Schalper;Michael Carleton;Ming Zhou;Tian Chen

  • In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.

    Kurt A. Schalper;Vamsidhar Velcheti;Daniel Carvajal;Hallie Wimberly

  • Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

    Sarah B Goldberg;Kurt A Schalper;Scott N Gettinger;Amit Mahajan

  • Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

    Kurt A. Schalper;Jason Brown;Daniel Carvajal-Hausdorf;Joseph McLaughlin

  • Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.

    M. F. Sanmamed;J. L. Perez-Gracia;K. A. Schalper;J. P. Fusco

  • PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

    Hallie Wimberly;Jason R. Brown;Kurt A Schalper;Herbert Haack

  • Interleukin-8 in cancer pathogenesis, treatment and follow-up.

    Carlos Alfaro;Miguel F. Sanmamed;María E. Rodríguez-Ruiz;Álvaro Teijeira

  • Oncolytic virus immunotherapy: future prospects for oncology

    Junaid Raja;Johannes M. Ludwig;Johannes M. Ludwig;Scott N. Gettinger;Kurt A. Schalper

  • Modulation of Brain Hemichannels and Gap Junction Channels by Pro-Inflammatory Agents and Their Possible Role in Neurodegeneration

    Juan A. Orellana;Pablo J. Sáez;Kenji F. Shoji;Kurt A. Schalper

  • Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

    Ila J Datar;Ila J Datar;Miguel F Sanmamed;Miguel F Sanmamed;Jun Wang;Brian S Henick;Brian S Henick

Frequent Co-Authors

David L. Rimm
David L. Rimm Yale University
Roy S. Herbst
Roy S. Herbst Yale University
Scott N. Gettinger
Scott N. Gettinger Yale University
Lieping Chen
Lieping Chen Yale University
Ignacio Melero
Ignacio Melero University of Oxford
Juan C. Sáez
Juan C. Sáez University of Valparaíso
Anant Madabhushi
Anant Madabhushi Emory University
Lajos Pusztai
Lajos Pusztai Yale University
Katerina Politi
Katerina Politi Yale University
Harriet M. Kluger
Harriet M. Kluger Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing studies in Biology and Biochemistry opens doors to a variety of dynamic career paths, many of which can be accessed or enhanced through flexible online degrees. Fields like medical coding and health information management are rapidly growing, in part due to the demand for skilled professionals who understand both science and technology. For those interested in this career, medical.coding salary trends show competitive compensation and career stability.

The healthcare sector continues to need qualified staff, making questions such as is medical billing and coding in demand highly relevant. Online learning options, such as health information management online programs, offer flexibility for those balancing studies, work, or family commitments.

Additionally, students with a foundation in biochemistry often consider advancing their knowledge through nutrition studies. Enrolling in an online nutrition masters program is a practical option, equipping graduates with expertise to succeed in both healthcare and wellness industries.

Best Scientists Citing Kurt A. Schalper

Trending Scientists